Amalgamated Financial’s Bio-Rad Laboratories Class A BIO Stock Holding History

Amalgamated Financial’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$3.25M	Buy	+5,774	New	+$3.48M	0.03%	694

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Amalgamated Financial's BIO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Bio-Rad Laboratories Class A (BIO) in Q1 2022: 5,774 shares worth $3.25M. The stake represents 0.03% of the portfolio and ranks #694 among its holdings.

516 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

Amalgamated Financial held 5,774 shares of Bio-Rad Laboratories Class A worth $3.25M as of Q1 2022.
Bio-Rad Laboratories Class A was a new Amalgamated Financial position in Q1 2022.
Bio-Rad Laboratories Class A made up 0.03% of Amalgamated Financial's portfolio in Q1 2022, its #694 holding.
516 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.